{"id":"travoprost","rwe":[{"pmid":"41832303","year":"2026","title":"Safety and Feasibility of the Exchange Procedure for the Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension.","finding":"","journal":"Ophthalmology and therapy","studyType":"Clinical Study"},{"pmid":"41779494","year":"2026","title":"Beyond pressure control: Periorbital impact of prostaglandins vs. laser trabeculoplasty.","finding":"","journal":"Arquivos brasileiros de oftalmologia","studyType":"Clinical Study"},{"pmid":"41474499","year":"2026","title":"Implants to Treat Glaucoma: Promising or Not?","finding":"","journal":"Drugs & aging","studyType":"Clinical Study"},{"pmid":"41465809","year":"2025","title":"Impact of Preservative-Free Travoprost on Intraocular Pressure and Ocular Surface in Primary Open-Angle Glaucoma Patients.","finding":"","journal":"Life (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41377220","year":"2025","title":"Travoprost intraocular implants: pioneering a new approach in ocular hypertension management.","finding":"","journal":"Annals of medicine and surgery (2012)","studyType":"Clinical Study"}],"_fda":{"id":"d78c5705-68ac-4363-b9ae-5facc60e2b79","risks":["Risk Summary There are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. In animal reproduction studies, subcutaneous (SC) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. Advise pregnant women of a potential risk to a fetus. Because animal reproductive studies are not always predictive of human response, travoprost should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.","Risk Summary There are no data on the effects of travoprost on the breastfed child or milk production. It is not known if travoprost is present in human milk following ophthalmic administration. A study in lactating rats demonstrated that radio-labeled travoprost and/or its metabolites were excreted in milk following subcutaneous administration. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for travoprost ophthalmic solution 0.004% and any potential adverse effects on the breast-fed child from travoprost ophthalmic solution 0.004%."],"set_id":"00dc284f-fd96-423b-bb8f-b90ee13439bf","openfda":{"nui":["N0000175454","M0017805"],"unii":["WJ68R08KX9"],"route":["OPHTHALMIC"],"rxcui":["284008"],"spl_id":["d78c5705-68ac-4363-b9ae-5facc60e2b79"],"brand_name":["Travoprost Ophthalmic Solution, 0.004%"],"spl_set_id":["00dc284f-fd96-423b-bb8f-b90ee13439bf"],"package_ndc":["0378-9651-32","0378-9651-50"],"product_ndc":["0378-9651"],"generic_name":["TRAVOPROST OPHTHALMIC SOLUTION, 0.004%"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Prostaglandins [CS]"],"substance_name":["TRAVOPROST"],"pharm_class_epc":["Prostaglandin Analog [EPC]"],"manufacturer_name":["Mylan Pharmaceuticals Inc."],"application_number":["ANDA205050"],"is_original_packager":[true]},"version":"7","pregnancy":["8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. In animal reproduction studies, subcutaneous (SC) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. Advise pregnant women of a potential risk to a fetus. Because animal reproductive studies are not always predictive of human response, travoprost should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data An embryo-fetal study was conducted in pregnant rats administered travoprost once daily by SC injection from gestation day (GD) 6 to 18, to target the period of organogenesis. At 10 mcg/kg (60 times the maximum recommended human ocular dose [MRHOD], based on estimated plasma C max ), travoprost was teratogenic in rats, evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, including fused sternebrae, domed head and hydrocephaly. Travoprost caused post-implantation loss at 10 mcg/kg. The no observed adverse effect level (NOAEL) for post-implantation loss was 3 mcg/kg (18 times the MRHOD, based on estimated plasma C max ). The maternal NOAEL was 10 mcg/kg. An embryo-fetal study was conducted in pregnant mice administered travoprost once daily by SC injection from GD 6 to 11, to target the period of organogenesis. At 1 mcg/kg (6 times the MRHOD, based on estimated plasma C max ), travoprost caused postimplantation loss and decreased fetal weight. The no observed adverse effect level (NOAEL) for malformations was 0.3 mcg/kg (2 times the MRHOD, based on estimated plasma C max ). The maternal NOAEL was 1 mcg/kg. Pre/postnatal studies were conducted in rats administered travoprost once daily by subcutaneous injection from GD 7 (early embryonic period) to postnatal Day 21 (end of lactation period). At doses of greater than or equal to 0.12 mcg/kg/day (0.7 times the MRHOD, based on estimated plasma C max ), adverse pregnancy outcomes (embryo-fetal lethality, abortion, and early delivery), low-birth weight and developmental delays were observed. The NOAEL for adverse pregnancy outcomes, low-birth weight and developmental delay was 0.1 mcg/kg (0.6 times the MHROD, based on estimated plasma C max ). The NOAEL for maternal toxicity was 0.72 mcg/kg (4 times the MHROD, based on estimated plasma C max )."],"description":["11 DESCRIPTION Travoprost is a synthetic prostaglandin F analog. Its chemical name is [1 R -[1α( Z ),2β(1 E ,3 R *),3α,5α]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethylester. It has a molecular formula of C 26 H 35 F 3 O 6 and a molecular weight of 500.55 g/mol. The chemical structure of travoprost is: Travoprost, USP is a pale yellow to yellowish viscous oil that is freely soluble in acetonitrile, toluene, ethyl acetate and methanol. It is practically insoluble in hexane and water. Travoprost ophthalmic solution, USP (ionic buffered solution) 0.004% is supplied as a clear colorless, sterile, buffered aqueous solution of travoprost with a pH of approximately 5.7 and an osmolality of approximately 290 mOsmol/kg. Travoprost ophthalmic solution, USP (ionic buffered solution) contains Active: travoprost USP, 0.04 mg/mL; Inactives: boric acid, polyoxyl 40 hydrogenated castor oil, propylene glycol, sodium hydroxide and/or hydrochloric acid (to adjust pH), sorbitol, water for injection and zinc chloride. chemical structure of travoprost"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Travoprost ophthalmic solution USP, (ionic buffered solution) 0.004% is a clear colorless, sterile, aqueous solution of travoprost, USP (0.04 mg/mL). Travoprost ophthalmic solution, USP (ionic buffered solution) is supplied as a 2.5 mL or 5 mL solution in a 5 mL natural colored low density polyethylene bottle with a turquoise, high density polyethylene, tamper evident screw cap and a low density polyethylene nozzle. 2.5 mL fill NDC 0378-9651-32 carton of one bottle 5 mL fill NDC 0378-9651-50 carton of one bottle Storage : Store at 2° to 25°C (36° to 77°F). After opening, travoprost ophthalmic solution, USP (ionic buffered solution) can be used until the expiration date on the bottle."],"geriatric_use":["8.5 Geriatric Use No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients."],"pediatric_use":["8.4 Pediatric Use Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use."],"effective_time":"20260115","clinical_studies":["14 CLINICAL STUDIES In clinical studies, patients with open-angle glaucoma or ocular hypertension and baseline pressure of 25 to 27 mmHg who were treated with travoprost ophthalmic solution 0.004% dosed once daily in the evening, demonstrated 7 to 8 mmHg reductions in IOP. In subgroup analyses of these studies, mean IOP reduction in black patients was up to 1.8 mmHg greater than in non-black patients. It is not known at this time whether this difference is attributed to race or to heavily pigmented irides. In a multi-center, randomized, controlled trial, patients with mean baseline IOP of 24 to 26 mmHg on timolol maleate ophthalmic solution 0.5% twice daily who were treated with travoprost ophthalmic solution 0.004% dosed daily adjunctively to timolol maleate ophthalmic solution 0.5% twice daily demonstrated 6 to 7 mmHg reductions in IOP."],"pharmacokinetics":["12.3 Pharmacokinetics Travoprost is absorbed through the cornea and is hydrolyzed to the active free acid. Data from 4 multiple dose pharmacokinetic studies (totaling 107 subjects) have shown that plasma concentrations of the free acid are below 0.01 ng/mL (the quantitation limit of the assay) in two-thirds of the subjects. In those individuals with quantifiable plasma concentrations (N = 38), the mean plasma C max was 0.018 ± 0.007 ng/mL (ranged 0.01 to 0.052 ng/mL) and was reached within 30 minutes. From these studies, travoprost is estimated to have a plasma half-life of 45 minutes. There was no difference in plasma concentrations between Days 1 and 7, indicating steady-state was reached early and that there was no significant accumulation. Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α (carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13, 14 double bond. The elimination of travoprost free acid from plasma was rapid and levels were generally below the limit of quantification within one hour after dosing. The terminal elimination half-life of travoprost free acid was estimated from fourteen subjects and ranged from 17 minutes to 86 minutes with the mean half-life of 45 minutes. Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid."],"adverse_reactions":["6 ADVERSE REACTIONS Most common adverse reaction (30% to 50%) is conjunctival hyperemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reaction observed in controlled clinical trials with travoprost ophthalmic solution 0.004% was ocular hyperemia, which was reported in 30% to 50% of patients. Up to 3% of patients discontinued therapy due to conjunctival hyperemia. Ocular adverse reactions reported at an incidence of 5% to 10% in these clinical trials included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus. Ocular adverse reactions reported at an incidence of 1% to 4% in clinical trials with travoprost ophthalmic solution 0.004% included abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry eye, iris discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage, and tearing. Non-ocular adverse reactions reported at an incidence of 1% to 5% in these clinical studies were allergy, angina pectoris, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu syndrome, depression, dyspepsia, gastrointestinal disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infections. 6.2 Postmarketing Experience Additional adverse reactions have been identified during post approval use of travoprost ophthalmic solution 0.004% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to travoprost, or a combination of these factors, include: arrhythmia, vomiting, epistaxis, tachycardia, and insomnia. In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed."],"contraindications":["4 CONTRAINDICATIONS None. None ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time. 12.3 Pharmacokinetics Travoprost is absorbed through the cornea and is hydrolyzed to the active free acid. Data from 4 multiple dose pharmacokinetic studies (totaling 107 subjects) have shown that plasma concentrations of the free acid are below 0.01 ng/mL (the quantitation limit of the assay) in two-thirds of the subjects. In those individuals with quantifiable plasma concentrations (N = 38), the mean plasma C max was 0.018 ± 0.007 ng/mL (ranged 0.01 to 0.052 ng/mL) and was reached within 30 minutes. From these studies, travoprost is estimated to have a plasma half-life of 45 minutes. There was no difference in plasma concentrations between Days 1 and 7, indicating steady-state was reached early and that there was no significant accumulation. Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α (carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13, 14 double bond. The elimination of travoprost free acid from plasma was rapid and levels were generally below the limit of quantification within one hour after dosing. The terminal elimination half-life of travoprost free acid was estimated from fourteen subjects and ranged from 17 minutes to 86 minutes with the mean half-life of 45 minutes. Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid."],"indications_and_usage":["1 INDICATIONS AND USAGE Travoprost ophthalmic solution (ionic buffered solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Travoprost ophthalmic solution (ionic buffered solution) is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent. ( 5.1 ) • Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. ( 5.2 ) 5.1 Pigmentation Travoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as travoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known. Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with travoprost ophthalmic solution 0.004% can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly [see Patient Counseling Information (17) ] . 5.2 Eyelash Changes Travoprost ophthalmic solution 0.004% may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment [see Patient Counseling Information (17) ] . 5.3 Intraocular Inflammation Travoprost ophthalmic solution 0.004% should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated. 5.4 Macular Edema Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. Travoprost ophthalmic solution 0.004% should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. 5.5 Angle-closure, Inflammatory or Neovascular Glaucoma Travoprost ophthalmic solution 0.004% has not been evaluated for the treatment of angle-closure, inflammatory or neovascular glaucoma. 5.6 Bacterial Keratitis There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface [see Patient Counseling Information (17) ] . 5.7 Use with Contact Lenses Contact lenses should be removed prior to instillation of travoprost ophthalmic solution 0.004% and may be reinserted 15 minutes following its administration."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Two-year carcinogenicity studies in mice and rats at subcutaneous doses of 10, 30, or 100 mcg/kg/day did not show any evidence of carcinogenic potential. However, at 100 mcg/kg/day, male rats were only treated for 82 weeks, and the maximum tolerated dose (MTD) was not reached in the mouse study. The high dose (100 mcg/kg) corresponds to exposure levels 326 times (mouse) and 547 times (rat) the human exposure at the MRHOD of 0.04 mcg/kg, based on estimated plasma C max for active travoprost free acid. Travoprost was not mutagenic in the Ames test, mouse micronucleus test or rat chromosome aberration assay. A slight increase in the mutant frequency was observed in one of two mouse lymphoma assays in the presence of rat S-9 activation enzymes. Travoprost did not affect mating or fertility indices in male or female rats at subcutaneous doses up to 3 mcg/kg/day (18 times the MRHOD based on estimated plasma C max ). At 10 mcg/kg/day (60 times the MRHOD, based on estimated plasma C max ), the mean number of corpora lutea was reduced, and the post-implantation losses were increased."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Potential for Pigmentation Advise the patient about the potential for increased brown pigmentation of the iris, which may be permanent. Inform the patient about the possibility of eyelid skin darkening, which may be reversible after discontinuation of travoprost ophthalmic solution 0.004% [see Warnings and Precautions (5.1) ] . Potential for Eyelash Changes Inform the patient about the possibility of eyelash and vellus hair changes in the treated eye during treatment with travoprost ophthalmic solution 0.004%. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment [see Warnings and Precautions (5.2) ] . Handling the Container Instruct the patient to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions [see Warnings and Precautions (5.6) ] . When to Seek Physician Advice Advise the patient that if they develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of travoprost ophthalmic solution 0.004% [see Warnings and Precautions (5.3 , 5.4 , 5.5) ] . Use with Contact Lenses Contact lenses should be removed prior to instillation of travoprost ophthalmic solution and may be reinserted 15 minutes following its administration [see Warnings and Precautions (5.7) ] . Use with Other Ophthalmic Drugs If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes between applications. Distributed by: Mylan Pharmaceuticals Inc., a Viatris Company Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited Bangalore, India 50107944 Revised: 1/2026 M:TRAVOS:R1"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the affected eye(s) once daily in the evening. Travoprost ophthalmic solution (ionic buffered solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect. Reduction of the IOP starts approximately 2 hours after the first administration with maximum effect reached after 12 hours. Travoprost ophthalmic solution (ionic buffered solution) may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart. One drop in the affected eye(s) once daily in the evening. ( 2 )"],"spl_product_data_elements":["Travoprost Ophthalmic Solution, 0.004% Travoprost Ophthalmic Solution, 0.004% TRAVOPROST TRAVOPROST POLYOXYL 40 HYDROGENATED CASTOR OIL BORIC ACID PROPYLENE GLYCOL SORBITOL ZINC CHLORIDE SODIUM HYDROXIDE HYDROCHLORIC ACID WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing travoprost 0.04 mg/mL. Ophthalmic solution containing travoprost 0.04 mg/mL ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. ( 8.4 ) 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk. In animal reproduction studies, subcutaneous (SC) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. Advise pregnant women of a potential risk to a fetus. Because animal reproductive studies are not always predictive of human response, travoprost should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data An embryo-fetal study was conducted in pregnant rats administered travoprost once daily by SC injection from gestation day (GD) 6 to 18, to target the period of organogenesis. At 10 mcg/kg (60 times the maximum recommended human ocular dose [MRHOD], based on estimated plasma C max ), travoprost was teratogenic in rats, evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, including fused sternebrae, domed head and hydrocephaly. Travoprost caused post-implantation loss at 10 mcg/kg. The no observed adverse effect level (NOAEL) for post-implantation loss was 3 mcg/kg (18 times the MRHOD, based on estimated plasma C max ). The maternal NOAEL was 10 mcg/kg. An embryo-fetal study was conducted in pregnant mice administered travoprost once daily by SC injection from GD 6 to 11, to target the period of organogenesis. At 1 mcg/kg (6 times the MRHOD, based on estimated plasma C max ), travoprost caused postimplantation loss and decreased fetal weight. The no observed adverse effect level (NOAEL) for malformations was 0.3 mcg/kg (2 times the MRHOD, based on estimated plasma C max ). The maternal NOAEL was 1 mcg/kg. Pre/postnatal studies were conducted in rats administered travoprost once daily by subcutaneous injection from GD 7 (early embryonic period) to postnatal Day 21 (end of lactation period). At doses of greater than or equal to 0.12 mcg/kg/day (0.7 times the MRHOD, based on estimated plasma C max ), adverse pregnancy outcomes (embryo-fetal lethality, abortion, and early delivery), low-birth weight and developmental delays were observed. The NOAEL for adverse pregnancy outcomes, low-birth weight and developmental delay was 0.1 mcg/kg (0.6 times the MHROD, based on estimated plasma C max ). The NOAEL for maternal toxicity was 0.72 mcg/kg (4 times the MHROD, based on estimated plasma C max ). 8.2 Lactation Risk Summary There are no data on the effects of travoprost on the breastfed child or milk production. It is not known if travoprost is present in human milk following ophthalmic administration. A study in lactating rats demonstrated that radio-labeled travoprost and/or its metabolites were excreted in milk following subcutaneous administration. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for travoprost ophthalmic solution 0.004% and any potential adverse effects on the breast-fed child from travoprost ophthalmic solution 0.004%. 8.4 Pediatric Use Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. 8.5 Geriatric Use No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients. 8.6 Hepatic and Renal Impairment Travoprost ophthalmic solution 0.004% has been studied in patients with hepatic impairment and also in patients with renal impairment. No clinically relevant changes in hematology, blood chemistry, or urinalysis laboratory data were observed in these patients."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL – 2.5 mL NDC 0378-9651-32 Travoprost Ophthalmic Solution, USP 0.004% (Ionic Buffered Solution) FOR TOPICAL EYE USE Sterile Rx only 2.5 mL Each mL contains: Active: Travoprost, USP 0.04 mg Inactives: boric acid, polyoxyl 40 hydrogenated castor oil, propylene glycol, sodium hydroxide and/or hydrochloric acid (to adjust for pH), sorbitol, water for injection and zinc chloride. Preserved in the bottle with an ionic buffered system. Recommended Dosage: Instill one drop in the affected eye(s) once daily in the evening. Retain the bottle in the carton until time of use. This package is not child resistant. Keep this and all medication out of the reach of children. Keep container tightly closed. Storage: Store at 2° to 25℃ (36° to 77°F). Distributed by: Mylan Pharmaceuticals Inc., a Viatris Company Morgantown, WV 26505 U.S.A. Viatris.com Made in India M:9651:32:1C:R1 Code No.: TN/DRUGS/TN00003234 Travoprost Ophthalmic Solution, USP 2.5 mL Carton Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Two-year carcinogenicity studies in mice and rats at subcutaneous doses of 10, 30, or 100 mcg/kg/day did not show any evidence of carcinogenic potential. However, at 100 mcg/kg/day, male rats were only treated for 82 weeks, and the maximum tolerated dose (MTD) was not reached in the mouse study. The high dose (100 mcg/kg) corresponds to exposure levels 326 times (mouse) and 547 times (rat) the human exposure at the MRHOD of 0.04 mcg/kg, based on estimated plasma C max for active travoprost free acid. Travoprost was not mutagenic in the Ames test, mouse micronucleus test or rat chromosome aberration assay. A slight increase in the mutant frequency was observed in one of two mouse lymphoma assays in the presence of rat S-9 activation enzymes. Travoprost did not affect mating or fertility indices in male or female rats at subcutaneous doses up to 3 mcg/kg/day (18 times the MRHOD based on estimated plasma C max ). At 10 mcg/kg/day (60 times the MRHOD, based on estimated plasma C max ), the mean number of corpora lutea was reduced, and the post-implantation losses were increased."]},"tags":[{"label":"Prostaglandin Analog","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin F2-alpha receptor","category":"target"},{"label":"PTGFR","category":"gene"},{"label":"PTGER3","category":"gene"},{"label":"S01EE04","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Solution","category":"form"},{"label":"Solution/ Drops","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Ocular hypertension","category":"indication"},{"label":"Open-angle glaucoma","category":"indication"},{"label":"Approved 2000s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":893.414,"date":"","count":491,"signal":"Treatment failure","source":"DrugCentral FAERS","actionTaken":"Reported 491 times (LLR=893)"},{"llr":491.885,"date":"","count":169,"signal":"Eye irritation","source":"DrugCentral FAERS","actionTaken":"Reported 169 times (LLR=492)"},{"llr":484.123,"date":"","count":136,"signal":"Intraocular pressure increased","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=484)"},{"llr":452.06,"date":"","count":168,"signal":"Ocular hyperaemia","source":"DrugCentral FAERS","actionTaken":"Reported 168 times (LLR=452)"},{"llr":229.947,"date":"","count":115,"signal":"Eye pain","source":"DrugCentral FAERS","actionTaken":"Reported 115 times (LLR=230)"},{"llr":208.873,"date":"","count":45,"signal":"Malignant mediastinal neoplasm","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=209)"},{"llr":207.373,"date":"","count":39,"signal":"Product delivery mechanism issue","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=207)"},{"llr":201.144,"date":"","count":86,"signal":"Glaucoma","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=201)"},{"llr":139.857,"date":"","count":45,"signal":"Blood immunoglobulin E increased","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=140)"},{"llr":126.131,"date":"","count":62,"signal":"Eye pruritus","source":"DrugCentral FAERS","actionTaken":"Reported 62 times (LLR=126)"},{"llr":114.223,"date":"","count":32,"signal":"Product packaging quantity issue","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=114)"},{"llr":97.374,"date":"","count":19,"signal":"Growth of eyelashes","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=97)"},{"llr":89.924,"date":"","count":27,"signal":"Product container issue","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=90)"},{"llr":87.361,"date":"","count":55,"signal":"Visual acuity reduced","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=87)"},{"llr":85.342,"date":"","count":26,"signal":"Foreign body sensation in eyes","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=85)"}],"commonSideEffects":[{"effect":"Conjunctival hyperemia","drugRate":"30% to 50%","severity":"common","_validated":true},{"effect":"Ocular hyperemia","drugRate":"30% to 50%","severity":"common","_validated":true},{"effect":"Decreased visual acuity","drugRate":"5% to 10%","severity":"common","_validated":true},{"effect":"Eye discomfort","drugRate":"5% to 10%","severity":"common","_validated":true},{"effect":"Foreign body sensation","drugRate":"5% to 10%","severity":"common","_validated":true},{"effect":"Pain","drugRate":"5% to 10%","severity":"common","_validated":true},{"effect":"Pruritus","drugRate":"5% to 10%","severity":"common","_validated":true},{"effect":"Abnormal vision","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Blepharitis","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Blurred vision","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Cataract","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Conjunctivitis","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Corneal staining","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Dry eye","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Iris discoloration","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Keratitis","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Lid margin crusting","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Ocular inflammation","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Photophobia","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Subconjunctival hemorrhage","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Tearing","drugRate":"1% to 4%","severity":"mild","_validated":true},{"effect":"Allergy","drugRate":"1% to 5%","severity":"mild","_validated":true},{"effect":"Angina pectoris","drugRate":"1% to 5%","severity":"mild","_validated":true},{"effect":"Anxiety","drugRate":"1% to 5%","severity":"mild","_validated":true},{"effect":"Arthritis","drugRate":"1% to 5%","severity":"mild","_validated":true},{"effect":"Bradycardia","drugRate":"1% to 5%","severity":"mild","_validated":true},{"effect":"Bronchitis","drugRate":"1% to 5%","severity":"mild","_validated":true},{"effect":"Cold/flu syndrome","drugRate":"1% to 5%","severity":"mild","_validated":true}],"contraindications":["Cystoid macular edema","Iritis","Uveitis"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. In animal reproduction studies, subcutaneous (SC) administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. Advise pregnant women of potential risk to fetus. Because animal reproductive studies are not always predictive of human response, travoprost should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.","Geriatric use":"No overall differences in safety or effectiveness have been observed between elderly and other adult patients.","Paediatric use":"Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use."}},"trials":[],"aliases":[],"patents":[{"applNo":"N218010","source":"FDA Orange Book","status":"Active","expires":"Jun 18, 2030","useCode":"U-4129","territory":"US","drugProduct":true,"patentNumber":"12201557","drugSubstance":true},{"applNo":"N218010","source":"FDA Orange Book","status":"Active","expires":"Oct 17, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11426306","drugSubstance":false},{"applNo":"N218010","source":"FDA Orange Book","status":"Active","expires":"Oct 17, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10206813","drugSubstance":false},{"applNo":"N218010","source":"FDA Orange Book","status":"Active","expires":"Feb 14, 2031","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12201555","drugSubstance":true},{"type":"Formulation","number":"9144561","applicant":"NOVARTIS PHARMACEUTICALS CORP","territory":"US","tradeName":"IZBA","expiryDate":"2029-03-13"},{"type":"Formulation","number":"8722735","applicant":"NOVARTIS PHARMACEUTICALS CORP","territory":"US","tradeName":"IZBA","expiryDate":"2029-10-10"},{"type":"Formulation","number":"8754123","applicant":"NOVARTIS PHARMACEUTICALS CORP","territory":"US","tradeName":"IZBA","expiryDate":"2029-05-19"},{"type":"Formulation","number":"8323630","applicant":"SANDOZ INC","territory":"US","tradeName":"TRAVATAN Z","expiryDate":"2027-09-20"},{"type":"Formulation","number":"8178582","applicant":"NOVARTIS PHARMACEUTICALS CORP","territory":"US","tradeName":"IZBA","expiryDate":"2029-10-10"},{"type":"Formulation","number":"8268299","applicant":"SANDOZ INC","territory":"US","tradeName":"TRAVATAN Z","expiryDate":"2029-10-13"},{"type":"Formulation","number":"8388941","applicant":"SANDOZ INC","territory":"US","tradeName":"TRAVATAN Z","expiryDate":"2027-09-20"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$19.8350/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$7,141","description":"TRAVOPROST 0.004% EYE DROP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TRAVOPROST","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:11:52.429323+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:11:52.429229+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Travoprost","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:11:59.499089+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:11:58.036078+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:11:52.501122+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRAVOPROST","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:11:58.455311+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:51.034103+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:51.034130+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:12:08.270679+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:51.034135+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Prostanoid FP receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:11:59.499041+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200799/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:11:59.165290+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA205050","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:51.034139+00:00"}},"allNames":"travatan","offLabel":[],"synonyms":["izba","travoprost","travaprost","travatan","travatanz"],"timeline":[{"date":"2001-03-16","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2001-11-27","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2006-09-21","type":"positive","source":"FDA Orange Book","milestone":"Travatan Z approved — 0.004%"},{"date":"2014-05-15","type":"positive","source":"FDA Orange Book","milestone":"Izba approved — 0.003% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2025-12-17","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 8 manufacturers approved"},{"date":"2026-12-13","type":"negative","source":"FDA Orange Book","milestone":"New Product exclusivity expires"},{"date":"2030-06-18","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 12201557 expires"},{"date":"2031-02-14","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 12201555 expires"}],"aiSummary":"Travatan (TRAVOPROST) is a prostaglandin analog, a small molecule drug that targets the prostaglandin F2-alpha receptor. It was originally developed and is currently owned by Glaukos. Travatan is FDA-approved for the treatment of ocular hypertension and open-angle glaucoma, and has been commercially available since 2001. The drug is now off-patent, with multiple generic manufacturers available. As a prostaglandin analog, Travatan works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure.","approvals":[{"date":"2001-03-16","orphan":false,"company":"","regulator":"FDA"},{"date":"2001-11-27","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Travatan","ecosystem":[{"indication":"Ocular hypertension","otherDrugs":[{"name":"betaxolol","slug":"betaxolol","company":"Alcon"},{"name":"bimatoprost","slug":"bimatoprost","company":""},{"name":"brimonidine","slug":"brimonidine","company":""},{"name":"brinzolamide","slug":"brinzolamide","company":"Alcon Pharms Ltd"}],"globalPrevalence":1280000000},{"indication":"Open-angle glaucoma","otherDrugs":[{"name":"acetazolamide","slug":"acetazolamide","company":"Teva Branded Pharm"},{"name":"apraclonidine","slug":"apraclonidine","company":"Alcon"},{"name":"betaxolol","slug":"betaxolol","company":"Alcon"},{"name":"bimatoprost","slug":"bimatoprost","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Prostaglandin F2-alpha receptor","novelty":"Follow-on","targets":[{"gene":"PTGFR","source":"DrugCentral","target":"Prostaglandin F2-alpha receptor","protein":"Prostaglandin F2-alpha receptor"},{"gene":"PTGER3","source":"DrugCentral","target":"Prostaglandin E2 receptor EP3 subtype","protein":"Prostaglandin E2 receptor EP3 subtype"}],"modality":"Small Molecule","drugClass":"Prostaglandin Analog [EPC]","explanation":"Travoprost free acid, prostaglandin analog is selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.","oneSentence":"Travatan works by increasing the outflow of fluid from the eye to reduce pressure.","technicalDetail":"Travatan (TRAVOPROST) is a selective FP receptor agonist, which increases the outflow of aqueous humor through the uveoscleral pathway, thereby reducing intraocular pressure."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Travoprost","title":"Travoprost","extract":"Travoprost, sold under the brand name Travatan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It is used as an eye drop. Effects generally occur within two hours."},"commercial":{"launchDate":"2001","_launchSource":"DrugCentral (FDA 2001-03-16, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2716","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TRAVOPROST","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRAVOPROST","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Travoprost","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T16:03:53.380039","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:12:08.402332+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"latanoprost","drugSlug":"latanoprost","fdaApproval":"1996-06-05","patentExpiry":"Sep 12, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bimatoprost","drugSlug":"bimatoprost","fdaApproval":"2001-03-16","patentExpiry":"Oct 31, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tafluprost","drugSlug":"tafluprost","fdaApproval":"2012-02-10","patentExpiry":"May 28, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"latanoprostene bunod","drugSlug":"latanoprostene-bunod","fdaApproval":"2017-11-02","patentExpiry":"Feb 21, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"netarsudil","drugSlug":"netarsudil","fdaApproval":"2017-12-18","patentExpiry":"Nov 10, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"exclusivity":[{"code":"NP","date":"Dec 13, 2026"}],"genericName":"travoprost","indications":{"approved":[{"id":"travoprost-reduction-of-elevated-iop","name":"Reduction of elevated IOP","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with open-angle glaucoma or ocular hypertension","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with open-angle glaucoma or ocular hypertension","diagnosticRequired":null,"brandNameForIndication":"Travatan"}],"offLabel":[],"pipeline":[]},"currentOwner":"Glaukos","drugCategory":"mature","labelChanges":[],"relatedDrugs":[{"drugId":"latanoprost","brandName":"latanoprost","genericName":"latanoprost","approvalYear":"1996","relationship":"same-class"},{"drugId":"bimatoprost","brandName":"bimatoprost","genericName":"bimatoprost","approvalYear":"2001","relationship":"same-class"},{"drugId":"tafluprost","brandName":"tafluprost","genericName":"tafluprost","approvalYear":"2012","relationship":"same-class"},{"drugId":"latanoprostene-bunod","brandName":"latanoprostene bunod","genericName":"latanoprostene bunod","approvalYear":"2017","relationship":"same-class"},{"drugId":"netarsudil","brandName":"netarsudil","genericName":"netarsudil","approvalYear":"2017","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07495852","phase":"PHASE3","title":"Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2026-02-17","conditions":["Glaucoma"],"enrollment":510,"completionDate":"2032-03"},{"nctId":"NCT07075718","phase":"PHASE2,PHASE3","title":"Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-06-12","conditions":["Glaucoma"],"enrollment":610,"completionDate":"2032-03"},{"nctId":"NCT07400926","phase":"","title":"Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-12-17","conditions":["Open Angle Glaucoma (OAG)","Ocular Hypertension (OH)"],"enrollment":30,"completionDate":"2026-07"},{"nctId":"NCT06848946","phase":"PHASE4","title":"Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-01-13","conditions":["Glaucoma, Open-angle","Ocular Hypertension (OHT)","Phacoemulsification Cataract Surgery"],"enrollment":132,"completionDate":"2027-06"},{"nctId":"NCT06066645","phase":"PHASE3","title":"Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2023-09-14","conditions":["Glaucoma, Open-Angle"],"enrollment":230,"completionDate":"2028-02"},{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":["Glaucoma"],"enrollment":1500,"completionDate":"2026-06"},{"nctId":"NCT07228221","phase":"PHASE4","title":"Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma","status":"RECRUITING","sponsor":"Jonathon Myers","startDate":"2026-01-05","conditions":["Open Angle Glaucoma","Pigmentary Glaucoma","Pseudoexfoliation Glaucoma"],"enrollment":20,"completionDate":"2031-12-31"},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":["Glaucoma"],"enrollment":28,"completionDate":"2024-10-04"},{"nctId":"NCT05335122","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2022-03-16","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":83,"completionDate":"2025-01-24"},{"nctId":"NCT03868124","phase":"PHASE3","title":"Clinical Study Comparing Two Models of a Travoprost Intraocular Implant","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2018-09-17","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":560,"completionDate":"2024-06-19"},{"nctId":"NCT03519386","phase":"PHASE3","title":"Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2018-07-26","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":590,"completionDate":"2024-04-02"},{"nctId":"NCT06582732","phase":"PHASE2","title":"Performance of the Travoprost Intraocular Implant","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2021-03-10","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":210,"completionDate":"2023-11-02"},{"nctId":"NCT04360174","phase":"PHASE1","title":"CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2018-04-25","conditions":["Ocular Hypertension","Open Angle Glaucoma"],"enrollment":19,"completionDate":"2021-05-24"},{"nctId":"NCT06061718","phase":"PHASE3","title":"Travoprost Intraocular Implant in Conjunction With Cataract Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glaukos Corporation","startDate":"2023-09-11","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":60,"completionDate":"2024-12-20"},{"nctId":"NCT06152861","phase":"PHASE2","title":"Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Glaukos Corporation","startDate":"2023-11-15","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":250,"completionDate":"2024-08"},{"nctId":"NCT00762645","phase":"PHASE4","title":"Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-02","conditions":["Angle-closure Glaucoma"],"enrollment":30,"completionDate":"2008-05"},{"nctId":"NCT00758342","phase":"PHASE4","title":"Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2006-05","conditions":["Intraocular Pressure"],"enrollment":37,"completionDate":"2008-03"},{"nctId":"NCT04615403","phase":"PHASE2","title":"Study of Exchange of Travoprost Intraocular Implant","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2020-11-19","conditions":["Open Angle Glaucoma"],"enrollment":33,"completionDate":"2022-02-28"},{"nctId":"NCT02754596","phase":"PHASE2","title":"Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2016-03-29","conditions":["Glaucoma Open-angle"],"enrollment":154,"completionDate":"2020-07-21"},{"nctId":"NCT04962009","phase":"","title":"Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Mati Therapeutics Inc.","startDate":"2021-09-08","conditions":["Elevated Intraocular Pressure (IOP)"],"enrollment":12,"completionDate":"2022-07-15"},{"nctId":"NCT05319470","phase":"","title":"Ocular Surface Disease and IOP Monitoring With Travoprost Without Conservatives","status":"COMPLETED","sponsor":"Democritus University of Thrace","startDate":"2022-03-15","conditions":["Glaucoma","Glaucoma; Drugs","Ocular Surface Disease"],"enrollment":25,"completionDate":"2023-05-15"},{"nctId":"NCT04061044","phase":"PHASE3","title":"A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2018-07-10","conditions":["Open Angle Glaucoma and Ocular Hypertension"],"enrollment":40,"completionDate":"2020-09-22"},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":["Ocular Surface Disease","Primary Open Angle Glaucoma"],"enrollment":50,"completionDate":"2022-08-24"},{"nctId":"NCT01444040","phase":"PHASE4","title":"Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2011-09","conditions":["Open-angle Glaucoma"],"enrollment":196,"completionDate":"2019-03-28"},{"nctId":"NCT02873806","phase":"PHASE4","title":"Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2013-03","conditions":["Open-angle Glaucoma"],"enrollment":53,"completionDate":"2019-11-08"},{"nctId":"NCT05241938","phase":"NA","title":"PSLT Compared to Prostaglandin Analogue Eye Drops","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2021-09-01","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":75,"completionDate":"2022-12-20"},{"nctId":"NCT02914509","phase":"PHASE3","title":"Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2016-11-07","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":565,"completionDate":"2019-03-30"},{"nctId":"NCT04868175","phase":"NA","title":"Interval Intraocular Pressure in Intravitreal Injection Study","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-10-01","conditions":["Glaucoma","Intraocular Pressure"],"enrollment":64,"completionDate":"2021-04-01"},{"nctId":"NCT00847483","phase":"PHASE4","title":"Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-01","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":375,"completionDate":"2002-08"},{"nctId":"NCT00757835","phase":"PHASE4","title":"24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2008-05","conditions":["Glaucoma"],"enrollment":40,"completionDate":"2009-03"},{"nctId":"NCT00981786","phase":"PHASE4","title":"24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-08","conditions":["Glaucoma"],"enrollment":51,"completionDate":"2010-12"},{"nctId":"NCT02796560","phase":"PHASE4","title":"Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2016-07-01","conditions":["Glaucoma, Primary Open Angle","Ocular Hypertension"],"enrollment":76,"completionDate":"2017-09-12"},{"nctId":"NCT04577027","phase":"PHASE4","title":"Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-01-01","conditions":["Vitiligo","Excimer Laser","Fractional CO2 Laser"],"enrollment":30,"completionDate":"2022-04-01"},{"nctId":"NCT04461249","phase":"","title":"Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2019-06-01","conditions":["Primary Open Angle Glaucoma"],"enrollment":60,"completionDate":"2020-04-01"},{"nctId":"NCT03965052","phase":"PHASE1","title":"Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-04-24","conditions":["Glaucoma"],"enrollment":24,"completionDate":"2019-08-29"},{"nctId":"NCT02371746","phase":"PHASE2","title":"Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma","status":"COMPLETED","sponsor":"Envisia Therapeutics","startDate":"2015-01-01","conditions":["Glaucoma and Ocular Hypertension"],"enrollment":41,"completionDate":"2019-02-13"},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":["Glaucoma, Open-Angle"],"enrollment":96,"completionDate":"2015-04"},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":["Open-angle Glaucoma","Ocular Hypertension"],"enrollment":173,"completionDate":"2018-07-13"},{"nctId":"NCT00440011","phase":"PHASE4","title":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":266,"completionDate":"2007-10"},{"nctId":"NCT00539526","phase":"PHASE4","title":"Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-09","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":106,"completionDate":"2008-09"},{"nctId":"NCT03150160","phase":"PHASE4","title":"Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-21","conditions":["Glaucoma"],"enrollment":1,"completionDate":"2017-12-04"},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"enrollment":290,"completionDate":"2018-02-27"},{"nctId":"NCT00798694","phase":"PHASE4","title":"How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2008-11","conditions":["Glaucoma"],"enrollment":58,"completionDate":"2011-02"},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":["Thyroid Eye Disease","Ocular Hypertension","Glaucoma"],"enrollment":0,"completionDate":"2016-12"},{"nctId":"NCT03274323","phase":"NA","title":"Trabeculectomy Versus 2-iStent and Prostaglandin Study","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2018-01-12","conditions":["Glaucoma, Open-Angle"],"enrollment":0,"completionDate":"2018-01-12"},{"nctId":"NCT01443988","phase":"PHASE4","title":"Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2011-09","conditions":["Open-angle Glaucoma"],"enrollment":101,"completionDate":"2017-04"},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":["Glaucoma"],"enrollment":150,"completionDate":"2020-06"},{"nctId":"NCT01298687","phase":"PHASE2","title":"Divided Dose of TRAVATAN®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":["Open-angle Glaucoma","Ocular Hypertension"],"enrollment":67,"completionDate":"2011-04"},{"nctId":"NCT01315574","phase":"PHASE4","title":"Effects of Anti-Glaucoma Medications on the Ocular Surface","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2011-02","conditions":["Glaucoma"],"enrollment":14,"completionDate":"2013-12"},{"nctId":"NCT00554411","phase":"","title":"Assessing Ocular Surface Changes After Changing Glaucoma Medications","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-11","conditions":["Glaucoma","Monotherapy With Xalatan From 1 to 18 Months","Ocular Surface Disease"],"enrollment":22,"completionDate":"2011-08"},{"nctId":"NCT02312544","phase":"PHASE2","title":"Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2014-11","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":72,"completionDate":"2015-12"},{"nctId":"NCT01845038","phase":"PHASE1","title":"Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2013-04","conditions":["Glaucoma"],"enrollment":41,"completionDate":"2014-05"},{"nctId":"NCT00759239","phase":"PHASE4","title":"Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":["Open-angle Glaucoma","Ocular Hypertension"],"enrollment":36,"completionDate":"2011-01"},{"nctId":"NCT00444665","phase":"PHASE4","title":"Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-05","conditions":["Glaucoma"],"enrollment":750,"completionDate":"2007-08"},{"nctId":"NCT00372827","phase":"PHASE4","title":"Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-02","conditions":["Primary Open-angle Glaucoma","Ocular Hypertension","Pigment Dispersion Glaucoma"],"enrollment":245,"completionDate":"2006-01"},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":["Glaucoma"],"enrollment":105,"completionDate":"2011-02"},{"nctId":"NCT00519753","phase":"PHASE4","title":"Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-08","conditions":["Glaucoma"],"enrollment":522,"completionDate":"2008-12"},{"nctId":"NCT00382226","phase":"PHASE4","title":"IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-09","conditions":["Glaucoma"],"enrollment":195,"completionDate":"2007-08"},{"nctId":"NCT00333125","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-04","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":319,"completionDate":"2007-02"},{"nctId":"NCT00293761","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-01","conditions":["Open-angle Glaucoma","Ocular Hypertension"],"enrollment":109,"completionDate":"2006-05"},{"nctId":"NCT00626067","phase":"PHASE4","title":"Study of Patient Use and Perception of the Travatan Dosing Aid","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2006-09","conditions":["Glaucoma"],"enrollment":45,"completionDate":"2007-02"},{"nctId":"NCT01474135","phase":"PHASE2","title":"AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2011-12","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":93,"completionDate":"2012-04"},{"nctId":"NCT02105311","phase":"PHASE4","title":"Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2014-03","conditions":["Intraocular Pressure"],"enrollment":60,"completionDate":"2016-02"},{"nctId":"NCT02003391","phase":"PHASE4","title":"Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-12","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":157,"completionDate":"2015-05"},{"nctId":"NCT01779778","phase":"","title":"Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-04","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":40,"completionDate":"2013-04"},{"nctId":"NCT01711177","phase":"NA","title":"Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma","status":"COMPLETED","sponsor":"Université de Montréal","startDate":"2012-10","conditions":["Primary Open Angle Glaucoma"],"enrollment":14,"completionDate":"2013-03"},{"nctId":"NCT01254370","phase":"PHASE2","title":"Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2010-11","conditions":["Glaucoma","Ocular Hypertension","Ocular Surface Disease"],"enrollment":105,"completionDate":"2011-06"},{"nctId":"NCT01658839","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-01","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":25,"completionDate":"2013-07"},{"nctId":"NCT00705757","phase":"PHASE4","title":"The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye","status":"COMPLETED","sponsor":"Summa Health System","startDate":"2008-03","conditions":["Glaucoma","Application Site Pigmentation Changes"],"enrollment":89,"completionDate":"2011-04"},{"nctId":"NCT02097719","phase":"PHASE4","title":"Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":100,"completionDate":"2014-12"},{"nctId":"NCT02140060","phase":"PHASE2","title":"6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-06","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":327,"completionDate":"2014-11"},{"nctId":"NCT01881126","phase":"PHASE4","title":"An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":93,"completionDate":"2014-10"},{"nctId":"NCT01995136","phase":"PHASE4","title":"Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-09","conditions":["Normal Tension Glaucoma","Ocular Hypertension"],"enrollment":32,"completionDate":"2014-06"},{"nctId":"NCT01664039","phase":"PHASE4","title":"An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":104,"completionDate":"2014-06"},{"nctId":"NCT01937312","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":["Ocular Hypertension","Open Angle Glaucoma"],"enrollment":282,"completionDate":"2014-05"},{"nctId":"NCT01652664","phase":"PHASE3","title":"Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":["Pediatric Glaucoma","Elevated IOP in Pediatric Patients","Ocular Hypertension in Pediatric Patients"],"enrollment":184,"completionDate":"2014-03"},{"nctId":"NCT01937299","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":["Ocular Hypertension","Open Angle Glaucoma"],"enrollment":307,"completionDate":"2014-04"},{"nctId":"NCT00887029","phase":"PHASE4","title":"A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Ophthalmic Consultants Centres, Canada","startDate":"2009-01","conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"enrollment":54,"completionDate":"2009-11"},{"nctId":"NCT01514721","phase":"PHASE4","title":"Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-06","conditions":["Glaucoma"],"enrollment":37,"completionDate":"2013-11"},{"nctId":"NCT01547598","phase":"PHASE4","title":"Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-12","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":135,"completionDate":"2013-07"},{"nctId":"NCT00465803","phase":"PHASE3","title":"A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":["Open-angle Glaucoma","Ocular Hypertension"],"enrollment":81,"completionDate":""},{"nctId":"NCT00928590","phase":"PHASE3","title":"Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-07","conditions":["Open-angle Glaucoma","Ocular Hypertension"],"enrollment":155,"completionDate":"2010-11"},{"nctId":"NCT00672997","phase":"PHASE3","title":"A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"enrollment":301,"completionDate":"2008-12"},{"nctId":"NCT00760539","phase":"PHASE3","title":"Safety and Efficacy of Travoprost/Timolol BAC-free","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-06","conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"enrollment":87,"completionDate":"2008-12"},{"nctId":"NCT00892762","phase":"PHASE3","title":"Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-06","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":434,"completionDate":"2011-05"},{"nctId":"NCT00670033","phase":"PHASE2","title":"Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-04","conditions":["Ocular Hypertension","Open-angle Glaucoma"],"enrollment":158,"completionDate":"2008-09"},{"nctId":"NCT01510145","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-02","conditions":["Open-angle Glaucoma","Ocular Hypertension"],"enrollment":191,"completionDate":"2013-05"},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":47,"completionDate":"2013-04"},{"nctId":"NCT01493427","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"enrollment":202,"completionDate":"2013-02"},{"nctId":"NCT02136589","phase":"PHASE4","title":"Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2008-09","conditions":["Hyperemia","Intraocular Pressure"],"enrollment":40,"completionDate":"2008-12"},{"nctId":"NCT01779284","phase":"PHASE4","title":"Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-01","conditions":["Glaucoma"],"enrollment":42,"completionDate":"2013-01"},{"nctId":"NCT00331240","phase":"PHASE3","title":"24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-03","conditions":["Primary Open Angle Glaucoma","Exfoliation Syndrome"],"enrollment":32,"completionDate":"2007-02"},{"nctId":"NCT00444184","phase":"PHASE4","title":"24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2007-03","conditions":["Glaucoma"],"enrollment":32,"completionDate":"2008-01"},{"nctId":"NCT01789736","phase":"PHASE2","title":"A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2013-02","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":234,"completionDate":"2013-06"},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":["Open-Angle Glaucoma","Ocular Hypertension","Pigment Dispersion Glaucoma"],"enrollment":60,"completionDate":"2012-11"},{"nctId":"NCT01978015","phase":"PHASE4","title":"Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-10","conditions":["Uveitis, Anterior","Cystoid Macular Edema"],"enrollment":69,"completionDate":"2013-01"},{"nctId":"NCT01312454","phase":"PHASE2","title":"Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2011-06","conditions":["Open-angle Glaucoma","Ocular Hypertension"],"enrollment":4,"completionDate":"2012-01"},{"nctId":"NCT01453855","phase":"PHASE3","title":"Travoprost 3-Month Safety and Efficacy Study","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-11","conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"enrollment":1099,"completionDate":"2012-08"},{"nctId":"NCT01464424","phase":"PHASE4","title":"Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-10","conditions":["Glaucoma","Ocular Hypertension","Open-Angle Glaucoma"],"enrollment":84,"completionDate":"2012-06"},{"nctId":"NCT01336569","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":["Glaucoma"],"enrollment":50,"completionDate":"2012-03"}],"_emaApprovals":[{"date":"2001-11-27","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Solution, Solution/ Drops","formulations":[{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Travoprost"},{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Travoprost Ophthalmic"},{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Travatan Z"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Travoprost Ophthalmic Solution USP, 0.004%Travoprost"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Travoprost Ophthalmic Solution, 0.004%"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Travatan Z"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Travoprost Ophthalmic Solution"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148702","MMSL":"15936","NDDF":"009114","UNII":"WJ68R08KX9","VUID":"4021261","CHEBI":"CHEBI:746859","VANDF":"4021261","INN_ID":"7775","RXNORM":"1539201","UMLSCUI":"C0937916","chemblId":"CHEMBL1200799","ChEMBL_ID":"CHEMBL1200799","KEGG_DRUG":"D01964","DRUGBANK_ID":"DB00287","PUBCHEM_CID":"5282226","SNOMEDCT_US":"129493000","IUPHAR_LIGAND_ID":"7102","MESH_DESCRIPTOR_UI":"D000069557"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Glaukos","relationship":"Current Owner"}],"publicationCount":747,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"S01EE04","allCodes":["S01EE04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 14","pmid":"41832303","title":"Safety and Feasibility of the Exchange Procedure for the Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension.","journal":"Ophthalmology and therapy"},{"date":"2026","pmid":"41779494","title":"Beyond pressure control: Periorbital impact of prostaglandins vs. laser trabeculoplasty.","journal":"Arquivos brasileiros de oftalmologia"},{"date":"2026 Feb","pmid":"41474499","title":"Implants to Treat Glaucoma: Promising or Not?","journal":"Drugs & aging"},{"date":"2025 Dec 6","pmid":"41465809","title":"Impact of Preservative-Free Travoprost on Intraocular Pressure and Ocular Surface in Primary Open-Angle Glaucoma Patients.","journal":"Life (Basel, Switzerland)"},{"date":"2025 Dec","pmid":"41377220","title":"Travoprost intraocular implants: pioneering a new approach in ocular hypertension management.","journal":"Annals of medicine and surgery (2012)"}],"companionDiagnostics":[],"genericManufacturers":8,"_genericFilersChecked":true,"genericManufacturerList":["Alembic","Apotex","Chartwell Rx","Gland","Lupin Ltd","Micro Labs","Mylan","Somerset Theraps Llc"],"status":"approved","companyName":"Glaukos","companyId":"","modality":"Small molecule","firstApprovalDate":"2001","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-03-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:12:08.402332+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}